This news from Merck combined with vaccinations and Covid therapies being worked on by Pfizer should help end Covid as a major issue for hospitals and mortuaries.
I'm sure Covid deniers will find the negatives in this news.
www.upi.com
Oct. 1 (UPI) -- Merck announced Friday it will ask the Food and Drug Administration to grant emergency use authorization for an anti-coronavirus drug that reduced hospitalizations by nearly 50% in clinical trials.
If approved, Molnupiravir, a joint effort between Merck and Ridgeback Biotherapeutics, would become the first orally taken antiviral medicine taken for COVID-19. In a Phase 3 study, 7.3% of patients taking Molnupiravir were hospitalized, while 14.1% of those taking a placebo had to be admitted to the hospital.
"With these compelling results, we are optimistic that Molnupiravir can become an important medicine as part of the global effort to fight the pandemic and will add to Merck's unique legacy of bringing forward breakthroughs in infectious diseases when they are needed most," Merck's CEO and president Robert M. Davis said in a statement.
Merck said in its Phase 3 study, no participants using Molnupiravir died through the first 29 days of the tests, while eight patients using a placebo died.
I'm sure Covid deniers will find the negatives in this news.
Merck to seek emergency use authorization for antiviral COVID-19 drug - UPI.com
Merck announced Friday it will ask the Food and Drug Administration to grant emergency use authorization for an anti-coronavirus drug that reduced hospitalizations by nearly 50% in clinical trials.
www.upi.com
If approved, Molnupiravir, a joint effort between Merck and Ridgeback Biotherapeutics, would become the first orally taken antiviral medicine taken for COVID-19. In a Phase 3 study, 7.3% of patients taking Molnupiravir were hospitalized, while 14.1% of those taking a placebo had to be admitted to the hospital.
"With these compelling results, we are optimistic that Molnupiravir can become an important medicine as part of the global effort to fight the pandemic and will add to Merck's unique legacy of bringing forward breakthroughs in infectious diseases when they are needed most," Merck's CEO and president Robert M. Davis said in a statement.
Merck said in its Phase 3 study, no participants using Molnupiravir died through the first 29 days of the tests, while eight patients using a placebo died.
